<DOC>
	<DOCNO>NCT02109367</DOCNO>
	<brief_summary>This study involve woman schedule surgery pelvic ovarian mass suspicious epithelial ovarian cancer ( EOC ) . The physician perform additional procedure patient know 'culdocentesis ' . This do prior schedule surgery patient general anesthesia . Culdocentesis procedure typically use check abnormal fluid space behind vagina . This pocket space call cul-de-sac . The purpose study determine level tumor marker , CA-125 HE4 , measurable cul-de-sac fluid . If tumor marker measurable cul-de-sac fluid correlate patient 's diagnosis , procedure may use future additional diagnostic tool EOC . In addition , single urine sample collect patient measure ratio `` good '' `` bad '' estrogen . Investigators hypothesize ratio also correlate EOC diagnosis . Study result could lead development alternative , minimally invasive low risk diagnostic tool patient ovarian mass suspicious malignancy .</brief_summary>
	<brief_title>Diagnostic Utility Culdocentesis Patients With Suspicious Adnexal Mass</brief_title>
	<detailed_description>This single cohort , exploratory pilot study 60 participant assess ovarian cancer marker , cancer antigen-125 ( CA-125 ) human epididymis protein 4 ( HE4 ) , measurable cul-de-sac washing collect via culdocentesis . Immediately prior schedule surgery , patient general anesthesia , long , thin needle insert wall vagina ( uterus ) access cul-de-sac . A saline wash perform fluid collect analysis tumor marker . CA-125 HE4 level compare serum level correlation diagnosis ovarian cancer . A urine sample also collect cohort measure estrogen metabolite . Estrogen metabolism associate cancer progression estrogen sensitive tissue . Estrogen metabolite , 2-hydroxyestrone ( 2-OHE1 ) `` good '' byproduct 16α-hydroxyestrone ( 16α-OHE1 ) know `` bad '' byproduct , implicate development breast cancer . Study investigator propose expand utility predictive ratio ovarian cancer measure potential imbalance metabolite . If result indicate association cancer diagnosis level CA-125 HE4 ratio estrogen metabolite urine , could allow new minimally invasive , low-risk diagnostic modality suspect ovarian cancer case . This would particularly invaluable patient high risk poor surgical outcome . Data pilot study confirm potential effect size need identify optimal cut-point useful prediction EOC within study population .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients age ≥ 30 . Adnexal mass suspect ovarian carcinoma . Patient schedule oophorectomy , bilateral salpingo oophorectomy ( BSO ) , hysterectomy , hysterectomy/BSO , stag debulking . Willingness sign Informed Consent document . Exclusion criterion : Patients previously diagnose malignancy within pelvis abdomen . Patients culdocentesis technically unfeasible due previous surgery ( extensive pelvic floor repair/colpocleisis ) anatomic abnormality make culdesac inaccessible .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>ovarian mass</keyword>
	<keyword>CA-125</keyword>
	<keyword>HE4</keyword>
	<keyword>culdocentesis</keyword>
	<keyword>biomarker ( )</keyword>
</DOC>